Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142643 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O3 |
| Mol.Wt. | 352.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142644 |
| CAS No | NA |
| Mol.F. | C14H17ClN4O3 |
| Mol.Wt. | 324.77 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142645 |
| CAS No | NA |
| Mol.F. | C16H22N4O4 |
| Mol.Wt. | 334.38 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142646 |
| CAS No | NA |
| Mol.F. | C15H18Cl2N4O4 |
| Mol.Wt. | 389.23 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142647 |
| CAS No | NA |
| Mol.F. | C14H10ClN3O5S |
| Mol.Wt. | 367.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142648 |
| CAS No | NA |
| Mol.F. | C14H9ClN2O3 |
| Mol.Wt. | 288.69 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142649 |
| CAS No | NA |
| Mol.F. | C16H14ClN3O5S |
| Mol.Wt. | 395.81 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142650 |
| CAS No | NA |
| Mol.F. | C14H10ClN3O4S |
| Mol.Wt. | 351.76 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142651 |
| CAS No | NA |
| Mol.F. | C28H18Cl2N4O9S2 |
| Mol.Wt. | 689.49 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142652 |
| CAS No | NA |
| Mol.F. | C14H8Cl2N2O3 |
| Mol.Wt. | 323.13 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142653 |
| CAS No | NA |
| Mol.F. | C17H16ClN3O5S |
| Mol.Wt. | 409.84 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142654 |
| CAS No | NA |
| Mol.F. | C15H12ClN3O5S |
| Mol.Wt. | 381.79 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142655 |
| CAS No | NA |
| Mol.F. | C14H8Cl2N2O4S |
| Mol.Wt. | 371.19 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142656 |
| CAS No | NA |
| Mol.F. | C14H11ClN4O4S |
| Mol.Wt. | 366.78 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142657 |
| CAS No | NA |
| Mol.F. | C14H8ClN3O5 |
| Mol.Wt. | 333.68 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142658 |
| CAS No | NA |
| Mol.F. | C7H7ClN4O6S2 |
| Mol.Wt. | 342.73 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |